2026 ICD-10-CM Diagnosis Code L12.2Chronic bullous disease of childhood

ICD-10-CM Codes›L00–L99›L10-L14›L12

ICD-10-CM L12.2
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

L12.2 is a billable ICD-10-CM diagnosis code for chronic bullous disease of childhood. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 606 through 607. The code is restricted by the Medicare Code Editor to pediatric patients (age 0 through 17). In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified inflammatory condition of skin.

Code Identity

ICD-10-CM Code
L12.2
Billable Status
Yes — Valid for Submission
Code Describes
Chronic bullous disease of childhood
Short Description
Chronic bullous disease of childhood
Same as the full description in the CMS dataset.
Parent Code
L12
Pemphigoid

Code Classification

ChapterL00–L99Diseases of the skin and subcutaneous tissue
SectionL10-L14Bullous disorders
CategoryL12Pemphigoid
This CodeL12.2Chronic bullous disease of childhood

Code EditsBilling

Medicare Code Editor checks that affect claim validity for L12.2.

Pediatric diagnoses
The Medicare Code Editor detects inconsistencies in pediatric cases by checking a patient's age and any diagnosis on the patient's record. The pediatric code edits apply to patients age range is 0–17 years inclusive (e.g., Reye's syndrome, routine child health exam).

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Bullous eruption
  • Bullous eruption of childhood
  • Bullous pemphigoid
  • Childhood bullous pemphigoid
  • Chronic bullous dermatosis of childhood
  • Chronic localized pemphigoid
  • Conjunctivitis associated with autoimmune skin disorder
  • Conjunctivitis associated with dermatitis herpetiformis
  • Dermatitis herpetiformis
  • Herpetiform eruption
  • Hydroa herpetiformis
  • Linear IgA dermatosis
  • Localized pemphigoid
  • Oral mucosal involvement by dermatitis herpetiformis
  • Pemphigoid
  • Pretibial pemphigoid
  • Vesicular eruption

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Juvenile dermatitis herpetiformis

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Dermatitis(eczematous)
      • herpetiformis (bullous) (erythematous) (pustular) (vesicular)
        • juvenile
    • Dermatitis(eczematous)
      • multiformis
        • juvenile
    • Dermatosis
      • herpetiformis
        • juvenile
    • Disease, diseased
      • bullous
        • chronic of childhood
    • Disease, diseased
      • chronic bullous of childhood
    • Pemphigoid
      • juvenile

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR SKN002
Other specified inflammatory condition of skin
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Dermatitis Herpetiformis

    rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. the disease is strongly associated with the presence of hla-b8 and hla-dr3 antigens. a variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis.

  • Dermatitis Herpetiformis

    a chronic autoimmune skin disorder characterized by the development of pruritic papulovesicular and bullous lesions in the elbows, knees, buttocks, and back. it is associated with an increased expression of hla-a1, hla-b8, and hla-dr3 antibodies.

  • Bullous Pemphigoid

    an autoimmune chronic skin disorder characterized by the presence of large blisters. it usually affects elderly people and tends to subside spontaneously.

  • COL17A1 wt Allele|BA16H23.2|BA16H23.2 (Collagen, Type XVII, Alpha 1 (BP180)) Gene|BP180|BPA-2|BPAG2|Bullous Pemphigoid Antigen 2 (180kD) Gene|Collagen Type XVII Alpha 1 Chain wt Allele|Collagen, Type XVII, Alpha 1 Gene|Collagen, Type XVII, Alpha-1 Gene|ERED|LAD-1

    human col17a1 wild-type allele is located in the vicinity of 10q25.1 and is approximately 55 kb in length. this allele, which encodes collagen alpha-1(xvii) chain protein, is involved in hemidesmosome formation and keratinocyte adhesion. mutation of the gene and immunoreactivity during revertant mosaicism is associated with both generalized atrophic benign and junctional epidermolysis bullosa. mutations in the gene are also associated with epithelial recurrent erosion dystrophy.

  • Collagen Alpha-1(XVII) Chain|180 kDa Bullous Pemphigoid Antigen 2|Alpha 1 Type XVII Collagen|Bullous Pemphigoid Antigen 2|COL17A1|Collagen Type XVII Alpha 1 Chain|Collagen Type XVII Alpha 1 Polypeptide|Type XVII Collagen Alpha-1

    collagen alpha-1(xvii) chain (1497 aa, ~150 kda) is encoded by the human col17a1 gene. this protein plays a role in the attachment of keratinocytes to the basement membrane.

  • Dystonin|230 kDa Bullous Pemphigoid Antigen|230/240 kDa Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1, 230/240kDa|DST|Dystonia Musculorum Protein|Hemidesmosomal Plaque Protein|Trabeculin-Beta

    dystonin (7570 aa, ~860 kda) is encoded by the human dst gene. this protein plays a structural role in cytoskeleton networks.

  • Benign Mucous Membrane Pemphigoid

    a chronic autoimmune disorder characterized by the development of blisters and ulcers in mucous membranes. it affects most often the gums, eyelids and genital mucosa sites.

  • Ocular Cicatricial Pemphigoid

    a chronic autoimmune disorder that belongs to the mucous membrane pemphigoid disorders. it is characterized by bilateral scarring and opacification of the conjunctivae. it presents with pain and burning sensation in the eyes and photophobia. it leads to blindness.

  • Pemphigoid

    a rare autoimmune blistering skin disorder that resembles pemphigus but is histologically and clinically distinguishable by lack of evidence of acantholysis and a generally benign course.

  • Pemphigoid Antibody Measurement|PEMAB|Pemphigoid Antibodies|Pemphigoid Antibodies

    the determination of the amount of pemphigoid antibodies present in a sample.

  • Pemphigoid Gestationis|Gestational Pemphigoid|Gestational Pemphigoid|Herpes Gestationis

    an autoimmune bullous dermatitis that develops during pregnancy, most often during the second and third trimesters.

  • Collagen Alpha-1(XVII) Chain|180 kDa Bullous Pemphigoid Antigen 2|Alpha 1 Type XVII Collagen|BASEMENT MEMBRANE ZONE BP180|BMZ BP180|BP180|BPAG2|Bullous Pemphigoid Antigen 2|Bullous Pemphigoid Antigen 2|COL17A1|Collagen Type XVII Alpha 1 Chain|Collagen Type XVII Alpha 1 Chain|Collagen Type XVII Alpha 1 Polypeptide|Type XVII Collagen Alpha-1

    collagen alpha-1(xvii) chain (1497 aa, ~150 kda) is encoded by the human col17a1 gene. this protein plays a role in the attachment of keratinocytes to the basement membrane.

  • Dystonin|230 kDa Bullous Pemphigoid Antigen|230/240 kDa Bullous Pemphigoid Antigen|BASEMENT MEMBRANE ZONE BP230|BMZ BP230|BP230|BPAG1|Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1, 230/240kDa|DST|Dystonia Musculorum Protein|Hemidesmosomal Plaque Protein|Trabeculin-Beta

    dystonin (7570 aa, ~860 kda) is encoded by the human dst gene. this protein plays a structural role in cytoskeleton networks.

  • Pemphigoid Antibody Measurement

    the determination of the amount of pemphigoid antibodies present in a sample.

  • Pemphigoid Autoantigens|PEMPHIGOID AUTOANTIGENS

    a group of autoimmune substances related to the pemphigoid diseases that may be mainly comprised of (but not limited to) the basement membrane zone antigens and proteins from the collagen superfamily.

Patient EducationClinical

Pemphigus

Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert L12.2 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
694.2 Juven dermat herpetiform
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About L12.2Overview

Is L12.2 (Pemphigoid) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report chronic bullous disease of childhood on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does L12.2 group to?

When chronic bullous disease of childhood is the principal diagnosis on an inpatient stay, it groups to MS-DRG 606, 607, with relative weights from 0.9064 to 1.5132 depending on complications. Higher weights mean higher Medicare reimbursement.

Who can L12.2 be reported for?

The Medicare Code Editor checks chronic bullous disease of childhood against patient demographics: this code is intended for pediatric patients (age 0 through 17). Claims outside these limits are flagged as inconsistent.

What is the ICD-9 equivalent of L12.2?

Under the General Equivalence Mappings, chronic bullous disease of childhood converts to ICD-9-CM 694.2 (juven dermat herpetiform). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.